Diagnostic accuracy and tumor-targeting kinetics of complete versus fragmented99mTc-labeled anti-carcinoembryonic antigen antibodies: An intraindividual comparison

Cancer Research

Volumn 55, Issue 23 SUPPL., 1995, Pages

  Behr, Thomas M ^a   Becker, Wolfgang S ^a,b   Klein, Michael W ^a   Bair, Hans J ^a   Scheele, Johannes R ^a   Wolf, Friedrich G ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CARCINOEMBRYONIC ANTIGEN MONOCLONAL ANTIBODY; TECHNETIUM 99M;

CANCER DIAGNOSIS; CLINICAL ARTICLE; COLORECTAL CARCINOMA; CONFERENCE PAPER; DIAGNOSTIC ACCURACY; HUMAN; PRIORITY JOURNAL;

ADENOCARCINOMA; ADULT; AGED; ANTIBODIES; CARCINOEMBRYONIC ANTIGEN; COLORECTAL NEOPLASMS; COMPARATIVE STUDY; ENDOMETRIAL NEOPLASMS; FEMALE; HUMAN; IMMUNOGLOBULIN FRAGMENTS; LUNG NEOPLASMS; MALE; MIDDLE AGE; RADIOIMMUNODETECTION; SENSITIVITY AND SPECIFICITY; SUPPORT, NON-U.S. GOV'T; TECHNETIUM;

EID: 0028864648     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Serafini, A. N. Monoclonal antibody imaging. Crossing the research/clinical barrier (Letter). Semin. Nucl. Med., 23: 88, 1993.
2. Schlom, J. Innovations in monoclonal antibody tumor targeting. JAMA, 261: 744-746, 1989.
3. Becker, W., Bair, H. J., Behr, T., and Wolf, F. Indikationen zur Immunszintigraphie bei entzündlichen Erkrankungen und beim kolorektalen Karzinom. Der Nuklearmediziner, 17: 251-272, 1994.
4. m-labelled monoclonal antibodies: a review. Nucl. Med. Commun., 14: 347-359, 1993.
5. Galandiuk, S. Immunoscintigraphy in the surgical management of colorectal cancer. J. Nucl. Med., 34: 541-544, 1993.
6. Goldenberg, D. M., Wlodowski, T. J., Sharkey, R. M., Silberstein, E. B., Serafini, A. N., Garty, I. I., Van Heertum, R. L., Higginbotham-Ford, E. A., Kotier, J. A., Balasubramanian, N., Swayne, L. C., Hansen, H. J., and Pinsky, C. M. Colorectal cancer imaging with iodine-123-labeled CEA monoclonal antibody fragments. J. Nucl. Med, 34: 61-70, 1993.
7. Goldenberg, D. M. Monoclonal antibodies in cancer detection and therapy. Am. J. Med., 94: 297-312, 1993.
8. 2 fragments of an anti-carcinoembryonic antigen monoclonal antibody: a multicenter study. Cancer Res., 49: 3095-3103, 1989.
9. Patt, Y. Z., Lamki, L. M., Shanken, J., Jessup, J. M., Charnsangaves, C., Anjani, J. A., Levin, B., Merchant, B., Halverson, C., and Murray, J. L. Imaging with In-111-labeled anti-carcinoembryonic antigen monoclonal antibody ZCE-025 of recurrent colorectal or carcinoembryonic antigen-producing cancer in patients with rising serum carcinoembryonic antigen levels and occult metastases. J. Clin. Oncol., 8: 1246-1254, 1990.
10. Moffat, F. L., Vargas-Cuba, R. D., Serafini, A. N., Casillas, J., Morillo, G., Benedetto, P., Robinson, D. S., Ardalan, B., Manten, H. D., Clark, K. C., and Pinsky, C. M. Radioimmunodetection of colorectal carcinoma using technetium-99m-labeled Fab′ fragments of the IMMU-4 anti-carcinoembryonic antigen monoclonal antibody. Cancer (Phila.), 73: 836s-845s, 1994.
11. Goldenberg, D. M. Radiolabeled antibodies. Sci. Am. Sci. & Med., 1: 64-73, 1994.
12. 99mTc-anti-CEA immunoscintigraphy in patients with liver metastases from colorectal carcinoma. Nucl. Med., 31: 80-83, 1992.
13. 2. In: A. Epenetos (ed.), Monoclonal Antibodies: Applications in Clinical Oncology, pp. 297-308. London: Chapman and Hall, Ltd., 1991.
14. Goldenberg, D. M., DeLand, F. H., Bennett, S. J., Primus, F. J., Owens, N., Flanigan, R. C., McRoberts, W., Bruce, A. W., and Mahan, D. E. Radioimmunodetection of prostatic cancer: in vivo use of radioactive antibodies against prostatic acid phosphatase for diagnosis and detection of prostatic cancer by nuclear imaging. JAMA, 250: 630-635, 1983.
15. Carasquillo, J. A., Krohn, K. A., Beaumier, P., Mcguffin, R. W., Brown, J. P., Hellström, K. E., Hellström, I., and Larson, S. Diagnosis of and therapy for solid tumors with radiolabeled antibodies and immune fragments. Cancer Treat. Rep., 68: 317-323, 1984.
16. 99mTc. Cancer Res., 50 (Suppl.): 909s-921s, 1990.
17. 111In-CYT-103). Antibody Immunoconj. Radiopharm., 2: 257-269, 1989.
18. Serafini, A. N., Vargas-Cuba, R., Benedetto, P., et al. Technetium-99m-labeled Fab′ fragment of anti-CEA monoclonal antibody for radioimmunodetection of colorectal adenocarcinoma. Antibody Immunoconj. Radiopharm., 4: 561-568, 1991.
19. Sharkey, R. M., Goldenberg, D. M., Vagg, R., Pawlyk, D., Wong, G., Siegel, J., Murthy, S., Levine, G., Izon, D., Gascon, P., Burger, K., Swayne, L., and Hansen, H. J. Phase I clinical evaluation of a new murine monoclonal antibody (Mu-9) against colon-specific antigen-p for targeting gastrointestinal carcinomas. Cancer (Phila.), 73: 864-877, 1994.
20. 2 in nude mice bearing human tumor xenografts. Cancer (Phila.), 73: 816-823, 1994.
21. 2 fragments in ovarian carcinoma patients. Cancer Res., 53: 5413-5418, 1993.
22. 2 in colorectal cancer patients. Cancer (Phila.), 73: 850-857, 1994.
23. Jain, R. K., and Baxter, L. T. Mechanisms of heterogenous distribution of monoclonal antibodies and other macromolecules in tumors: significance of elevated interstitial pressure. Cancer Res., 48: 7022-7032, 1988.
24. Jain, R. K. Determinants of tumor blood flow (Review). Cancer Res., 48:2641-2658, 1988.
25. van Osdol, W., Fujimori, K., and Weinstein, J. N. An analysis of monoclonal antibody distribution in microscopic tumor nodules: consequences of a "binding site barrier." Cancer Res., 51: 4776-4784, 1991.
26. Juweid, M., Neumann, R., Paik, C., Perez-Bacete, M. J., Sato, J., van Osdol, W., and Weinstein, J. N. Micropharmacology of monoclonal antibodies in solid tumors: direct experimental evidence for a binding site barrier. Cancer Res., 52: 5144-5153, 1992.
27. Primus, F. J., Newell, K. D., Blue, A., and Goldenberg, D. M. Immunological heterogeneity of carcinoembryonic antigen determinants on carcinoembryonic antigen distinguished by monoclonal antibodies. Cancer Res., 43: 686-692, 1983.
28. Bosslet, K., Lüben, G., Schwarz, A., Steinsträsser, A., Harthus, T., Kuhlmann, L., and Sedlacek, H. H. Immunohistochemical localization and molecular characteristics of three monoclonal antibody-defined epitopes detectable in carcinoembryonic antigen (CEA). Int. J. Cancer, 36: 75-84, 1985.
29. Gasparini, M., Buraggi, G. L., Regalia, E., Maffioli, L., Balzarini, L., and German, L. Comparison of radioimmunodetection with other imaging methods in evaluating local relapses of colorectal carcinoma. Cancer (Phila.), 73: 846-849, 1994.
30. Mariani, G., Callegaro, L., Mazzucca, N., Cecconato, E., Moka, N., Davis, M., Fusani, L., Deleide, G., Buraggi, G. L., and Bianchi, R. Tissue distribution of radiolabelled anti-CEA monoclonal antibodies in man. Protein Biol. Fluids, 32: 483-486, 1984.
31. m-labelled anti-CEA monoclonal antibody for tumour immunoscintigraphy: first clinical results. Nucl. Med. Commun., 10: 345-352, 1989.
32. Schwarz, A., and Steinsträsser, A. A novel approach to Tc-99m-labeled monoclonal antibodies. J. Nucl. Med., 28: 721, 1987.
33. 2 fragments of an anti CEA MoAb. Br. J. Cancer, 52: 649, 1985.
34. Riva, P., Paganelli, G., Callegaro, L., et al. Immunoscintigraphy of adenocarcinomas by means of anti-CEA monoclonal antibody F023C5. Nucl. Med. Commun., 9: 577-589, 1988.
35. 2 fragments of the anti-CEA MoAb F023C5. First clinical results. In: H. Bergmann and H. Sinzinger (eds.), Proceedings of the 21st Badgastein Symposium. Basel: Birkhaeuser Verlag, pp. 179-185, 1995.
36. Rhodes, B., Zamora, P., Newell, K., and Valdez, F. Technetium-99m labeling of murine monoclonal antibody fragments. J. Nucl. Med., 27: 685-693, 1986.
37. m: does fragmentation really occur? Nucl. Med. Commun., 15: 865-870, 1994.
38. Pimm, M. V., Rajput, R. S., Frier, M., and Gribben, S. J. Anomalies in reduction-mediated technetium-99m labelling of monoclonal antibodies. Eur. J. Nucl. Med., 18: 973-976, 1991.
39. Mardirossian, G., Wu, C., Rusckowski, M., and Hnatowich, D. J. The stability of Tc-99m directly labelled to an Fab′ antibody via stannous ion and mercaptoethanol reduction. Nucl. Med. Commun., 13: 503-512, 1992.
40. Hnatowich, D. J., Mardirossian, G., Rusckowski, M., Fogarasi, M., Virzi, F., and Winnard, J. Directly and indirectly technetium-99m-labeled antibodies: a comparison of in vitro and animal in vivo properties. J. Nucl. Med., 34: 109-119, 1993.
41. 2 and Fab′ fragments relative to immunoglobulin G in reactions with surface-bound antigen. Eur. J. Nucl. Med., 19: 402-408, 1992.
42. 1 versus Fab′ fragments. J. Nucl. Med., 35: 56P, 1994.
43. Griffiths, G. L., Goldenberg, D. M., Diril, H., and Hansen, H. J. Technetium-99m, rhenium-186, and rhenium-188 direct-labeled antibodies. Cancer (Phila.), 73: 761-768, 1994.
44. 2 radioimmunoconjugate by direct labeling methods. Nucl. Med. Biol., 21: 649-655, 1994.